Intercept Pharmaceuticals, Inc. (ICPT), which develops treatments for chronic liver diseases, Monday announced positive initial results from OBADIAH, an ongoing Phase 2a trial of obeticholic acid or OCA as a treatment for primary bile acid diarrhea or PBAD.
The results showed that there have been significantly increased levels of fibroblast growth factor 19 or FGF19 and improvement in clinical symptoms in patients with PBAD, the company said in a statement.
OBADIAH is an investigator-initiated and sponsored open label Phase 2a trial being conducted by Professor Julian Walters at the Imperial College of London in the United Kingdom. PBAD commonly known as idiopathic bile acid malabsorption, is a common chronic diarrheal condition due to excessive bile acid production and loss.
For comments and feedback: editorial@rttnews.com